Stimulant & Meth Detox in Palm Beach, FL

Stimulant use disorder encompasses a broad spectrum — from illicitly manufactured methamphetamine to commonly prescribed ADHD medications like Adderall, Ritalin, and Vyvanse. Despite the differences in source, social context, and potency, all stimulant drugs share a common mechanism: they flood the brain’s dopamine system, producing powerful short-term effects followed by significant neurological disruption. Dr. Mark G. Agresti, M.D., a board-certified psychiatrist with more than 30 years of experience in Palm Beach, provides comprehensive psychiatric treatment for stimulant use disorder — from acute withdrawal through long-term recovery — using the personalized, concierge-level care that makes real change possible.

Methamphetamine (Crystal Meth) — Neurotoxicity and Psychosis Risk

Methamphetamine is among the most neurotoxic drugs in common use. Unlike cocaine, which merely blocks dopamine reuptake, methamphetamine actually drives dopamine release from storage vesicles while simultaneously blocking its reuptake — producing a far larger dopamine surge than cocaine, and one that lasts much longer (hours rather than minutes). Chronic methamphetamine use causes measurable, lasting damage to dopaminergic and serotonergic neurons. Neuroimaging studies of long-term meth users show reduced dopamine transporter density and dopamine receptor availability in areas of the brain governing reward, motivation, and executive function.

The consequences of this neurotoxicity are clinically significant. Long-term meth users often display cognitive deficits — impaired memory, reduced processing speed, diminished executive function — that persist for months after stopping. A particularly dangerous feature of methamphetamine use is its propensity to induce psychosis: paranoia, auditory and visual hallucinations, and disorganized thinking that can be clinically indistinguishable from schizophrenia during active use. In some patients, meth-induced psychosis persists long after the drug has been cleared from the body, requiring active psychiatric treatment.

Acute methamphetamine withdrawal produces severe depression, profound fatigue, hypersomnia, cognitive impairment, and intense drug cravings. The depression can be severe enough to produce suicidal ideation, particularly in patients with underlying mood disorders. Psychiatric supervision during acute meth withdrawal is essential — not just for comfort, but for safety.

Adderall Dependence — Prescription Stimulant Misuse

Amphetamine salts (Adderall, Adderall XR) are among the most widely prescribed medications in the United States, primarily for ADHD and narcolepsy. At therapeutic doses, used as prescribed, amphetamines are safe and effective. But dependence develops when use escalates beyond prescribed doses, when medications are obtained without a prescription, or when the stimulant is used for purposes other than treatment — academic performance, weight loss, or recreational euphoria.

Adderall dependence is pharmacologically similar to methamphetamine dependence, albeit typically less severe due to lower doses. The withdrawal profile — fatigue, depression, hypersomnia, cognitive slowing, inability to concentrate, and strong cravings — can be particularly distressing for individuals who have come to rely on stimulants for baseline function. An important clinical consideration is that many patients with Adderall dependence have underlying, undiagnosed or inadequately treated ADHD. Their stimulant use may have begun as genuine self-medication of ADHD symptoms. Stopping Adderall in this context will unmask or worsen ADHD, and sustainable recovery requires proper ADHD treatment with appropriate, non-abused medications or therapeutic approaches.

Dr. Agresti evaluates every Adderall-dependent patient for underlying ADHD and designs a treatment plan that addresses both the stimulant use disorder and any co-occurring ADHD — a “taper and treat” approach that stabilizes the patient rather than leaving them with untreated neurological deficits after stopping the stimulant.

Ritalin and Methylphenidate Dependence

Methylphenidate (Ritalin, Concerta, Focalin, Daytrana) is the other major class of prescription stimulant. Like amphetamines, methylphenidate works by blocking dopamine reuptake in the prefrontal cortex and striatum, increasing dopamine availability in circuits governing attention and impulse control. When used at therapeutic doses for ADHD, methylphenidate is well-tolerated and effective. When misused — taken at higher doses, crushed and insufflated, or used by individuals without ADHD — the dopamine surge is larger and the reinforcing effects more pronounced.

Methylphenidate dependence generally produces a less severe withdrawal syndrome than amphetamine dependence, partly because methylphenidate has a shorter duration of action and its dopaminergic effects, while significant, are somewhat less pronounced than amphetamine. However, the withdrawal is still clinically meaningful: fatigue, depression, difficulty concentrating, and cravings can disrupt function for days to weeks.

The same ADHD co-occurrence issue applies to Ritalin dependence as to Adderall dependence. Dr. Agresti assesses every patient for underlying ADHD and provides appropriate, non-abused treatment options as part of the recovery plan. Stopping a stimulant that was genuinely helping ADHD, without treating the ADHD, sets patients up for relapse.

Vyvanse (Lisdexamfetamine) Dependence

Vyvanse (lisdexamfetamine) is a prodrug: lisdexamfetamine itself is pharmacologically inert until it is cleaved in the body to release d-amphetamine. This prodrug design was specifically intended to reduce abuse potential, because the conversion step limits how rapidly amphetamine reaches the brain compared to direct amphetamine formulations. For most patients, this design succeeds — Vyvanse has a somewhat lower abuse potential than Adderall at equivalent doses.

However, dependence can still develop, particularly with escalating doses over time. The withdrawal profile from Vyvanse is essentially that of d-amphetamine withdrawal: fatigue, depression, cognitive slowing, hypersomnia, and cravings. Because of Vyvanse’s long duration of action, the withdrawal may feel more prolonged and diffuse than with shorter-acting stimulants — less of an acute crash and more of a gradual depressive heaviness that settles in over days after stopping.

As with other prescription stimulants, Dr. Agresti evaluates Vyvanse-dependent patients for underlying ADHD, and designs a recovery plan that addresses both dimensions of the clinical picture.

Stimulant Withdrawal Symptoms — What to Expect

Despite differences in potency and specific pharmacology, all stimulant drugs produce a recognizable withdrawal syndrome when stopped after regular use. Understanding what to expect removes a major source of anxiety and helps patients stay the course:

• The crash (first 24–48 hours): An abrupt drop in mood, energy, and alertness. Patients typically feel exhausted but may have difficulty sleeping. Dysphoria and irritability are common. With methamphetamine, this phase can be severe, with profound depression and potential psychosis.
• Acute withdrawal (days 2–7): Depression deepens. Hypersomnia (sleeping 12–18 hours a day) is common. Appetite increases markedly. Concentration is severely impaired. Drug cravings are most intense during this phase, particularly in the late afternoon and evening.
• Anhedonia: The inability to feel pleasure — a direct consequence of dopamine system dysregulation — is one of the most demoralizing features of stimulant withdrawal. Activities that once brought enjoyment feel flat and gray. This symptom can persist for weeks and is a significant driver of relapse.
• Cognitive impairment: Difficulty concentrating, slow processing speed, and poor working memory can persist for weeks, particularly in heavy methamphetamine users. This can significantly impair work performance and is a source of distress for patients who were relying on stimulants to function.
• Protracted cravings: Even after the acute withdrawal subsides, cravings can emerge powerfully in response to environmental cues — stress, people, places, and emotions associated with use. This conditioned craving response is a neurological phenomenon requiring ongoing psychiatric support to manage.

Psychiatric Treatment Approach

There are currently no FDA-approved medications specifically for stimulant use disorder. This does not mean that psychiatric treatment is unnecessary — on the contrary, it means that the psychiatric management of co-occurring conditions and withdrawal-related symptoms is the most important tool available.

Dr. Agresti’s treatment approach for stimulant use disorder includes:

• Psychiatric stabilization during acute withdrawal: Management of severe depression, anxiety, insomnia, and — in methamphetamine cases — psychosis during the acute withdrawal period, using evidence-based medications appropriate to each symptom.
• Treatment of co-occurring depression: Stimulant-induced anhedonia and withdrawal depression often overlap with pre-existing or vulnerability to major depression. Antidepressant treatment during the withdrawal period can be lifesaving for some patients and significantly improves the odds of sustained recovery. See depression treatment for more information.
• Treatment of meth-induced or co-occurring psychosis: Patients who experience psychotic symptoms during methamphetamine withdrawal require antipsychotic treatment. Dr. Agresti manages this carefully, distinguishing between transient drug-induced psychosis and underlying psychotic illness, and tapering antipsychotics appropriately once the psychosis has resolved.
• ADHD evaluation and treatment: For patients with prescription stimulant dependence, a careful ADHD evaluation is essential. If ADHD is present, it must be treated — not with the abused stimulant, but with appropriate medications and strategies. Proper ADHD treatment removes a major driver of stimulant relapse.
• Ongoing craving management and relapse prevention: Psychiatric follow-up during the first 90 days of stimulant abstinence — when cue-induced cravings are most powerful — is critical for sustained recovery.

Concierge Stimulant Recovery Program

Recovery from stimulant use disorder is a process, not an event. Dr. Agresti’s concierge program provides the sustained, high-quality psychiatric support that this process requires:

• One flat fee for the acute detox and stabilization phase — no surprise billing, no annual membership.
• Direct cell phone access to Dr. Agresti — during acute withdrawal, when depression and cravings are most severe, being able to reach your physician directly provides both safety and genuine clinical support.
• 24/7 availability during acute withdrawal — particularly important for meth detox, where psychosis and severe depression can emerge rapidly.
• Concurrent psychiatric treatment — ADHD, depression, anxiety, and psychosis are treated alongside the stimulant use disorder, not sequentially.
• Outpatient program — no residential facility required. Stimulant detox, while psychologically intense, does not typically produce the acute medical emergencies of opioid or alcohol withdrawal, making outpatient care appropriate for most patients.
• Telehealth for ongoing care — most follow-up appointments can be conducted via telehealth, making care accessible throughout Florida.

Dr. Agresti’s office is located at 44 Cocoanut Row, Suite M-202, Palm Beach, FL 33480. His concierge psychiatry practice provides the individualized, expert care that stimulant recovery demands.

Recovery Is Possible — Call Today

Stimulant use disorder — whether from methamphetamine, Adderall, Ritalin, or Vyvanse — responds to expert psychiatric treatment. The neurological disruption that drives the addiction can heal, the co-occurring conditions can be treated, and sustainable recovery is achievable with the right support.

Dr. Agresti has helped patients in Palm Beach and throughout Florida rebuild their lives after stimulant addiction. He brings the same board-certified expertise, clinical rigor, and personal accessibility to every patient.

Schedule your consultation: Call or text 561-760-4107.
After-hours emergency line: 561-386-7743.
Office: 44 Cocoanut Row, Suite M-202, Palm Beach, FL 33480.
Telehealth available statewide in Florida.